AVIGEN(avgn) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVIGEN(avgn)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (144)	9/6/1999 3:22:00 AM
From: JMarcus	Read Replies (1) of 228

Rick, at an Informed Investors seminar last Spring, I met a fellow claiming to be AVGN's accountant. He was extremely bullish about AVGN's patent estate. He claimed that the AAV-vector patents had been thoroughly reviewed by the company's lenders and were considered rock solid. His personal prediction was that after the efficacy of the vector is vindicated in the now pending Phase I trials, a big pharma company would buy out the Avigen at a price in the neighborhood of $50/share. Standing by itself, this chatter doesn't deserve much credibility. But considering it in the context of your own research into the company's patent position, a pattern starts to emerge. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next